| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jeremy Koppel, Heather Bradshaw, Terry E Goldberg, Houman Khalili, Philippe Marambaud, Michael J Walker, Miguel Pazos, Marc L Gordon, Erica Christen, Peter Davie. Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study. Lipids in health and disease. vol 8. 2009-02-27. PMID:19144193. |
neuropathological, animal, and cell culture studies point to a role for the body's own endogenous cannabinoids (ecbs) system in alzheimer's disease (ad) pathology and treatment. |
2009-02-27 |
2023-08-12 |
Not clear |
| Yannick Marchalant, Francesca Cerbai, Holly M Brothers, Gary L Wen. Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. Neurobiology of aging. vol 29. issue 12. 2009-01-23. PMID:17561311. |
stimulation of cannabinoid receptors may provide clinical benefits in age-related diseases that are associated with brain inflammation, such as alzheimer's disease. |
2009-01-23 |
2023-08-12 |
rat |
| Jeremy Koppel, Peter Davie. Targeting the endocannabinoid system in Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 15. issue 3. 2009-01-06. PMID:18997302. |
targeting the endocannabinoid system in alzheimer's disease. |
2009-01-06 |
2023-08-12 |
Not clear |
| Jeremy Koppel, Peter Davie. Targeting the endocannabinoid system in Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 15. issue 3. 2009-01-06. PMID:18997302. |
there is a growing body of evidence suggesting that endocannabinoid interventions may have particular relevance to alzheimer's disease. |
2009-01-06 |
2023-08-12 |
Not clear |
| Jeremy Koppel, Peter Davie. Targeting the endocannabinoid system in Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 15. issue 3. 2009-01-06. PMID:18997302. |
here we present a review of endocannabinoid physiology, the evidence that underscores its utility as a potential target for intervention in alzheimer's disease, and suggest future pathways of research. |
2009-01-06 |
2023-08-12 |
Not clear |
| Tiziana Bisogno, Vincenzo Di Marz. The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses. Current pharmaceutical design. vol 14. issue 23. 2008-11-17. PMID:18781980. |
the role of the endocannabinoid system in alzheimer's disease: facts and hypotheses. |
2008-11-17 |
2023-08-12 |
human |
| Tiziana Bisogno, Vincenzo Di Marz. The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses. Current pharmaceutical design. vol 14. issue 23. 2008-11-17. PMID:18781980. |
unlike other neuroinflammatory disorders, like parkinson's disease, huntington's disease and multiple sclerosis, little is still known of the role of the endocannabinoid system in alzheimer's disease (ad). |
2008-11-17 |
2023-08-12 |
human |
| Yannick Marchalant, Holly M Brothers, Gary L Wen. Inflammation and aging: can endocannabinoids help? Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 62. issue 4. 2008-08-19. PMID:18400455. |
the basis for the manipulation of the endocannabinoid system in the brain in combination with existing treatments for alzheimer's disease will be discussed in this review. |
2008-08-19 |
2023-08-12 |
Not clear |
| E Núñez, C Benito, R M Tolón, C J Hillard, W S T Griffin, J Romer. Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience. vol 151. issue 1. 2008-04-22. PMID:18068305. |
specifically, data obtained in human brain tissue sections from alzheimer's disease patients showed that the expression of cannabinoid receptors of the cb(2) type is induced in activated microglial cells while fatty acid amide hydrolase (faah) expression is increased in reactive astrocytes. |
2008-04-22 |
2023-08-12 |
human |
| Natalya M Kogan, Raphael Mechoula. Cannabinoids in health and disease. Dialogues in clinical neuroscience. vol 9. issue 4. 2008-04-11. PMID:18286801. |
numerous diseases, such as anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (parkinson's disease, huntington's disease, tourette's syndrome, alzheimer's disease), epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders, to name just a few, are being treated or have the potential to be treated by cannabinoid agonists/antagonists/cannabinoid-related compounds. |
2008-04-11 |
2023-08-12 |
Not clear |
| V A Campbell, A Gowra. Alzheimer's disease; taking the edge off with cannabinoids? British journal of pharmacology. vol 152. issue 5. 2008-02-25. PMID:17828287. |
alzheimer's disease; taking the edge off with cannabinoids? |
2008-02-25 |
2023-08-12 |
Not clear |
| V A Campbell, A Gowra. Alzheimer's disease; taking the edge off with cannabinoids? British journal of pharmacology. vol 152. issue 5. 2008-02-25. PMID:17828287. |
the propensity of cannabinoids to reduce beta-amyloid-evoked oxidative stress and neurodegeneration, whilst stimulating neurotrophin expression neurogenesis, are interesting properties that may be beneficial in the treatment of alzheimer's disease. |
2008-02-25 |
2023-08-12 |
Not clear |
| V A Campbell, A Gowra. Alzheimer's disease; taking the edge off with cannabinoids? British journal of pharmacology. vol 152. issue 5. 2008-02-25. PMID:17828287. |
targeting cannabinoid receptors on microglia may reduce the neuroinflammation that is a feature of alzheimer's disease, without causing psychoactive effects. |
2008-02-25 |
2023-08-12 |
Not clear |
| V A Campbell, A Gowra. Alzheimer's disease; taking the edge off with cannabinoids? British journal of pharmacology. vol 152. issue 5. 2008-02-25. PMID:17828287. |
thus, cannabinoids offer a multi-faceted approach for the treatment of alzheimer's disease by providing neuroprotection and reducing neuroinflammation, whilst simultaneously supporting the brain's intrinsic repair mechanisms by augmenting neurotrophin expression and enhancing neurogenesis. |
2008-02-25 |
2023-08-12 |
Not clear |
| Cristina Benito, Estefanía Núñez, María Ruth Pazos, Rosa María Tolón, Julián Romer. The endocannabinoid system and Alzheimer's disease. Molecular neurobiology. vol 36. issue 1. 2007-12-18. PMID:17952652. |
the endocannabinoid system and alzheimer's disease. |
2007-12-18 |
2023-08-12 |
human |
| Mauro Maccarrone, Natalia Battista, Diego Centonz. The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. Progress in neurobiology. vol 81. issue 5-6. 2007-07-06. PMID:17276576. |
in particular, the effect of agonists/antagonists of endocannabinoid receptors, or of inhibitors of endocannabinoid metabolism, will be discussed in the context of onset and progression of huntington's disease, and will be compared with other neurodegenerative diseases like parkinson's disease, alzheimer's disease, and amyotropic lateral sclerosis. |
2007-07-06 |
2023-08-12 |
Not clear |
| Lisa M Eubanks, Claude J Rogers, Albert E Beuscher, George F Koob, Arthur J Olson, Tobin J Dickerson, Kim D Jand. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Molecular pharmaceutics. vol 3. issue 6. 2007-03-26. PMID:17140265. |
compared to currently approved drugs prescribed for the treatment of alzheimer's disease, thc is a considerably superior inhibitor of abeta aggregation, and this study provides a previously unrecognized molecular mechanism through which cannabinoid molecules may directly impact the progression of this debilitating disease. |
2007-03-26 |
2023-08-12 |
Not clear |
| C Velez-Pardo, M Jimenez Del Ri. Avoidance of Abeta[(25-35)] / (H(2)O(2)) -induced apoptosis in lymphocytes by the cannabinoid agonists CP55,940 and JWH-015 via receptor-independent and PI3K-dependent mechanisms: role of NF-kappaB and p53. Medicinal chemistry (Shariqah (United Arab Emirates)). vol 2. issue 5. 2007-01-30. PMID:17017986. |
cannabinoids have been suggested as potential neuroprotective compounds in alzheimer's disease (ad). |
2007-01-30 |
2023-08-12 |
Not clear |
| J Fernández-Ruiz, S Gonzále. Cannabinoid control of motor function at the basal ganglia. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596785. |
this three-fold evidence has provided support to the idea that cannabinoid-based compounds, which act at key steps of the endocannabinoid transmission [receptors, transporter, fatty acid amide hydrolase (faah)], might be of interest because of their potential ability to alleviate motor symptoms and/or provide neuroprotection in a variety of neurological pathologies directly affecting basal ganglia structures, such as parkinson's disease and huntington's chorea, or indirectly, such as multiple sclerosis and alzheimer's disease. |
2006-04-19 |
2023-08-12 |
Not clear |
| Cristina Benito, Woong-Ki Kim, Wong-Ki Kim, Iván Chavarría, Ceceila J Hillard, Ken Mackie, Rosa M Tolón, Kenneth Williams, Ken Williams, Julián Romer. A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 25. issue 10. 2006-03-02. PMID:15758162. |
these results resemble previous data obtained in alzheimer's disease human tissue samples and suggest that the endocannabinoid system may participate in the development of human immunodeficiency virus-induced encephalitis, because activation of cb2 receptors expressed by immune cells is likely to reduce their antiviral response and thus could favor the cns entry of infected monocytes. |
2006-03-02 |
2023-08-12 |
human |